Novartis AG has described pyridine-3-carboxylate compounds acting as voltage-dependent L-type calcium channel subunit α-1C channel (Cav1.2) activators reported to be useful for the treatment of schizophrenia, major depression, attention deficit hyperactivity disorder, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer’s disease and Brugada syndrome.